Tiotropium + Formoterol More Effective than Ipratropium + Salbutamol in COPD

18 Mar, 14

0

0

Tiotropium + Formoterol is More Effective than Ipratropium + Salbutamol in COPD

Objective

To compare the bronchodilator response of a single dose of Tiotropium + Formoterol (Duova; Cipla Ltd., India) pressurized metered dose inhaler (pMDI) with four doses of Ipratropium + Salbutamol administered via dry powder inhaler (Rotahaler; Cipla Ltd., India) in moderate-to-severe COPD patients.

Patients and Methods

Randomized, double-blind, cross-over study.
18 moderate to severe COPD patients.
Patients received a single dose of Tiotropium + Formoterol (18/12 mcg) or four doses of Ipratropium + Salbutamol (20/100 mcg) on two separate days, at least three days apart.

Results

A single dose of Tiotropium + Formoterol produced an equivalent bronchodilator response as four doses of Ipratropium + Salbutamol as measured by AUC_0-24 hrs for FEV₁ (p = 0.79) and for FVC (p = 0.59).

Mean % change in FEV1 from baseline for 2 treatments over a period of 24hours

Trough FEV₁, FVC values were significantly higher with single dose of Tiotropium + Formoterol as compared to Ipratropium + Salbutamol.

Conclusion

Once daily Tiotropium + Formoterol pMDI produces an equivalent bronchodilation response as four times a day of Ipratropium + Salbutamol.
Trough FEV₁ and FVC values are superior with Tiotropium + Formoterol pMDI.

P3496, presented at European Respiratory Society (ERS) Conference, 2008

0

0

Related Topics